首页> 外文会议>Conference on Biophotonics >Development of cell-based quantitative evaluation method for cell cycle-arrest type cancer drugs for apoptosis by high precision surfaceplasmon resonance sensor
【24h】

Development of cell-based quantitative evaluation method for cell cycle-arrest type cancer drugs for apoptosis by high precision surfaceplasmon resonance sensor

机译:高精度表面等离子体共振传感器基于细胞的细胞周期阻滞型抗癌药物定量评价方法的建立

获取原文

摘要

In vitro rapid and quantitative cell-based assay is demanded to verify the efficacy prediction of cancer drugs since a cancer patient may have unconventional aspects of tumor development. Here, we show the rapid and non-label quantitative verifying method and instrumentation of apoptosis for cell cycle-arrest type cancer drugs (Roscovitine and D-allose) by reaction analysis of living liver cancer cells cultured on a sensor chip with a newly developed high precision (50 ndeg s~(-1) average fluctuation) surface plasmon resonance (SPR) sensor. The time-course cell reaction as the SPR angle change rate for 10 min from 30 min cell culture with a drug was significantly related to cell viability. By the simultaneous detection of differential SPR angle change and fluorescence by specific probes using the new instrument, the SPR angle was related to the nano-order potential decrease in inner mitochondrjal membrane potential. The results obtained are universally valid for the cell cycle-arrest type cancer drugs, which mediate apoptosis through different cell-signaling pathways, by a liver cancer cell line of Hep G2 (P < 0.001). This system towards the application to evaluate personal therapeutic potentials of drugs using cancer cells from patients in clinical use.
机译:由于癌症患者可能具有肿瘤发展的非常规方面,因此需要体外快速定量的基于细胞的测定法来验证癌症药物的功效预测。在这里,我们通过在新开发的高灵敏度传感器芯片上培养的活肝癌细胞的反应分析,展示了细胞周期停滞型癌细胞药物(Roscovitine和D-allose)的快速,非标记定量验证方法和细胞凋亡检测仪器。高精度(50 ndeg s〜(-1)平均起伏)表面等离子体共振(SPR)传感器。从用药物进行30分钟细胞培养起10分钟内SPR角变化率随时间变化的细胞反应与细胞生存力显着相关。通过使用新仪器同时检测特定探针的差异SPR角度变化和荧光,SPR角度与内部线粒体膜电位的纳米级电位降低有关。获得的结果对于肝癌细胞Hep G2系通过不同的细胞信号传导途径介导凋亡的细胞周期阻滞型抗癌药物普遍有效(P <0.001)。该系统适用于使用临床患者使用的癌细胞来评估药物的个人治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号